1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted equity awards granted under one of our long-term incentive plans, during the three months ended September 30, 2020.
+Added: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended March 31, 2021.
Refer to Part I, Item 2.
−Removed: "Liquidity and Capital Resources" for further information.
+Added: "Liquidity and Capital Resources" for further details of the share repurchase program.
Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
2/1/2021–2/28/2021 240,688 $ 470.36 239,625 $ 1,387,271,680
−Removed: 9/1/2020–9/30/2020 179,828 (a)
−Removed: $ 558.55 179,824 (a)
+Added: 3/1/2021–3/31/2021 450,640 $ 467.68 450,640 $ 1,176,514,240
Total 691,328 (a)
−Removed: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is related to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock awards or restricted stock units granted under one of our long-term incentive plans.
+Added: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
Exhibit Number Description
−Removed: 4.1 Indenture, dated August 12, 2020, between Regeneron Pharmaceuticals, Inc.
−Removed: ( the " Registrant ") and U.S.
−Removed: Bank National Association.
−Removed: (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)
−Removed: 4.2 First Supplemental Indenture, dated August 12, 2020, between the Registrant and U.S.
−Removed: Bank National Association.
−Removed: (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)
−Removed: 4.3 Form of 1.750% Senior Note due 2030 (included in Exhibit 4.2).
−Removed: 4.4 Form of 2.800% Senior Note due 2050 (included in Exhibit 4.2).
−Removed: Base Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International.
−Removed: Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International.
−Removed: License Agreement, dated as of August 18, 2020, by and among the Registrant, F.
−Removed: Hoffman-La Roche Ltd, and Genentech, Inc.
+Added: Supply Agreement, dated as of January 12, 2021, by and between Regeneron Pharmaceuticals, Inc.
+Added: (the "Registrant") and the U.S.
+Added: Army Contracting Command, New Jersey.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
3 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019;
−Removed: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2020 and 2019;
−Removed: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2020 and 2019;
−Removed: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019;
+Added: (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020;
+Added: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2021 and 2020;
+Added: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2021 and 2020;
+Added: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020;
and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
3 unchanged sentences
REGENERON PHARMACEUTICALS, INC.
−Removed: November 5, 2020 By:
+Added: May 6, 2021 By:
/s/ Robert E.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.